Wednesday, April 30, 2014     12:55-14:45

LS1-Lunch Session-Sponsored by – Medtronic, Hall D

Place of Minimal Invasive Technologies in Patients Continuum of Care

Chairs: Michael Glikson; Amit Segev, Israel

Optimizing Outcomes for the Endovascular Repair of Type B Dissection
Ian Loftus, St. Georges, London, UK

The Role of Minimally Invasive ICMs in Arrhythmia Diagnosis and Management
Helmut Puererfellner, Elisabethinen Hospital, Linz, Austria

Benefits of Ablation vs. Medication for the Treatment of Atrial Fibrillation
Panos E. Vardas, President, European Society of Cardiology

CoreValve US Pivotal Trial High Risk Study Results
Haim Danenberg, Hadassah Hebrew University Medical Center, Jerusalem, Israel

LS2-Lunch Session-Sponsored by –  Pfizer, Hall E

Patient Tailored Approach in Anti-coagulation Treatment – Decision Making in AFib

Chairs: TBA

TBA
Arthur Pollak, Hadassah University Hospital, Jerusalem, Israel

TBA
Eli Lev, Kampus Golda Hasharon, Rabin Medical Center, Petach Tikva, Israel

TBA
Doron Netzer, Meir Medical Center, Kfar-Saba, Israel

LS3-Lunch Session – Sponsored by – AstraZeneca, Hall F

Novel Antiplatelet Agents for the Treatment of STEMI Patients

Chairs: TBA

The Effect of Ticagrelor in ACS – Platelet and Non Platelet Dependent Mechanisms
Doron Zahger

Why do I Use Ticagrelor in STEMI Patients
Elad Asher

Panel Discussion:
Modarator: Eugenia Nikolsky
Panel Members: Giora Weisz, Ronen Rubinstien, Zaza Iakobishvili

Thursday, May 1, 2014, 12:55-14:40

LS4- Lunch Session – Sponsored by – Rafa Labs, Hall D

Multidisciplinary Approach in Stroke Prevention in Atrial Fibrillation

Chairs: Doron Zagher; Nathan Bornstein; Aharon Lubetsky, Israel

The Use of NOACs in an ACS Patient
Doron Zagher, Soroka Medical Center, Beer Sheva, Israel

STROKE in AF – The “Event” We Better Skip
Nathan Bornstein, Tel –Aviv Medical Center, Tel Aviv, Israel

The Use of Noacs in a Patient with an Elevated Risk of Bleeding: What are the Solutions?
Aharon Lubetsky, Sheba Medical Center, Tel Hashomer, Israel

LS5-Lunch Session Sponsored by – Eli Lilly, Hall E

How to Optimally Tailor Antiplatelet Therapy in Patients with NSTEMI

Chairs: Dominick J. Angiolillo, USA; Shlomi Matezky; Ariel Rugin, Israel

How to Optimally Tailor Antiplatelet Therapy in Patients with NSTEMI: What have we learned?
Dominick J. Angiolillo, University of Florida College of Medicine, Jacksonville, CA, USA

Case Presentation

Panel Discussion

LS6-Lunch Session – Sponsored by Itamar Medical, Hall F

Endothelial Function Assessment – Ready for Clinical Use

Chairs: Peter Ganz, USA; Ran Kornowski, Israel

In the Management of CV Risk
Michael Shechter, Chaim Sheba Medical Center, Tel Hashomer, Israel

As an Additional Marker to Target in Secondary Prevention
Amir Lerman, Mayo Clinic, Rochester, USA

Sleep Apnea Endothelial Dysfunction Association – Targeting the Two makes it Even Better
Giora Pillar, Carmel Medical Center, Haifa, Israel